Table 1 Characteristics of study subjects according to treatment of latent tuberculosis infection
Variables | Eligible for TLTBI | Initiated TLTBI | Completed TLTBI | |||
|---|---|---|---|---|---|---|
| Â | N | (%) | n | (%) | n | (%) |
Sex | Â | Â | Â | Â | Â | Â |
   Male | 141 | (77.9) | 92 | (75.4) | 52 | (74.3) |
   Female | 40 | (22.1) | 30 | (24.6) | 18 | (25.7) |
Age group (years) | Â | Â | Â | Â | Â | Â |
   ≤ 30 | 48 | (26.5) | 39 | (32.0) | 20 | (28.6) |
   31-35 | 53 | (29.3) | 33 | (27.0) | 15 | (21.4) |
   36-40 | 40 | (22.1) | 22 | (18.0) | 13 | (18.6) |
   ≥ 41 | 40 | (22.1) | 28 | (23.0) | 22 | (31.4) |
Country of origin | Â | Â | Â | Â | Â | Â |
   Spain | 154 | (85.1) | 101 | (82.8) | 58 | (82.9) |
   Other | 27 | (14.9) | 21 | (17.2) | 12 | (17.1) |
Educational level | Â | Â | Â | Â | Â | Â |
   None/incomplete primary education | 24 | (13.3) | 14 | (11.5) | 6 | (8.6) |
   Primary education completed | 80 | (44.2) | 54 | (44.3) | 33 | (47.1) |
   Secondary/university education completed | 48 | (26.5) | 34 | (27.9) | 18 | (25.7) |
   Unknown | 29 | (16.0) | 20 | (16.3) | 13 | (18.6) |
Employment status | Â | Â | Â | Â | Â | Â |
   Employed | 73 | (40.3) | 49 | (40.2) | 33 | (47.1) |
   Unemployed | 83 | (45.9) | 56 | (45.9) | 27 | (38.6) |
   Other | 20 | (11.0) | 13 | (10.6) | 7 | (10.0) |
   Unknown | 5 | (2.8) | 4 | (3.3) | 3 | (4.3) |
HIV transmission route | Â | Â | Â | Â | Â | Â |
   IDU | 101 | (55.8) | 59 | (48.4) | 28 | (40.0) |
   MSM | 22 | (12.2) | 17 | (13.9) | 7 | (10.0) |
   Heterosexual sex | 53 | (29.3) | 44 | (36.1) | 34 | (48.6) |
   Other/unknown | 5 | ( 2.8) | 2 | (1.6) | 1 | (1.4) |
Viral load (copies) | Â | Â | Â | Â | Â | Â |
   < 50 | 17 | (9.4) | 8 | (6.6) | 6 | (8.6) |
   50-9,999 | 57 | (31.5) | 43 | (35.2) | 29 | (41.4) |
   10,000-54,999 | 45 | (24.9) | 30 | (24.6) | 15 | (21.4) |
   ≥ 55,000 | 58 | (32.0) | 39 | (32.0) | 19 | (27.1) |
   Unknown | 4 | (2.2) | 2 | (1.6) | 1 | (1.4) |
CD4 (cells/μL) |  |  |  |  |  |  |
   < 100 | 22 | (12.2) | 11 | (9.0) | 5 | (7.1) |
   100-199 | 24 | (13.3) | 16 | (13.1) | 10 | (14.3) |
   200-499 | 75 | (41.4) | 52 | (42.6) | 28 | (40.0) |
   ≥ 500 | 60 | (33.1) | 43 | (35.2) | 27 | (38.6) |
Hepatitis B carriers | Â | Â | Â | Â | Â | Â |
   Yes | 14 | (7.7) | 9 | (7.4) | 3 | (4.3) |
   No | 163 | (90.1) | 112 | (91.8) | 67 | (95.7) |
   Unknown | 4 | (2.2) | 1 | (0.8) | 0 | (0.0) |
Hepatitis C virus antibodies | Â | Â | Â | Â | Â | Â |
   Yes | 107 | (59.1) | 62 | (50.8) | 31 | (44.3) |
   No | 69 | (38.1) | 57 | (46.7) | 38 | (54.3) |
   Unknown | 5 | (2.8) | 3 | (2.5) | 1 | (1.4) |
TOTAL | 181 | (100.0) | 122 | (100.0) | 70 | (100.0) |